PT-141 10mg Review

PT-141, known chemically as bremelanotide, represents one of the most studied cyclic heptapeptide melanocortin agonists in the reproductive pharmacology literature. Its path from sunburn-protection analog to a compound that attracted two Phase III clinical programs is unusually well-documented, giving researchers a comparatively rich body of published data to work from. This review synthesizes the current mechanistic understanding, key clinical and preclinical findings, pharmacokinetic parameters, purity expectations, and reconstitution guidance relevant to laboratory investigators sourcing the 10 mg research vial.

The article does not advocate for, nor describe, self-administration. Every mechanism claim, dose figure, and outcome reference is anchored to a numbered citation in the reference list below.

Editor's Verdict

PT-141 occupies a genuinely unusual position in the research-peptide landscape. Unlike many compounds where clinical translation remains speculative, bremelanotide has a completed regulatory dossier: the FDA approved it in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. ^[1] That approval makes the compound's published pharmacology substantially more detailed than most research peptides at this price point. The 10 mg vial from Apollo Peptide Sciences prices at $45.00, which is competitive for a compound of this molecular complexity and established purity standards.

For laboratory researchers, the value proposition is clear: a cyclic heptapeptide with well-characterized receptor binding kinetics, a documented Phase II and Phase III clinical dataset, and a defined mechanism through the central melanocortin system. The mechanistic questions that remain open (CNS vs. peripheral weighting of effects, dose-response shape in non-human animal models, MC3R vs. MC4R contribution ratios) make it a productive subject for controlled in-vitro or animal-protocol research.

The primary limitation for basic-science researchers is that almost all the controlled human-outcome data concerns HSDD specifically, leaving broader MC4R behavioral, metabolic, and cardiovascular applications supported mainly by preclinical evidence. Researchers investigating those secondary endpoints should approach the literature with appropriate skepticism about translational relevance.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

Historical Development from MT-II

PT-141 emerged from a lineage of synthetic melanocortin peptides engineered at the University of Arizona by Victor Hruby and colleagues in the 1980s and 1990s. The starting template was alpha-melanocyte-stimulating hormone (α-MSH), a tridecapeptide endogenous agonist at all five melanocortin receptor subtypes (MC1R-MC5R). Early structure-activity studies identified the His-Phe-Arg-Trp tetrapeptide core as the minimal pharmacophore responsible for receptor binding. ^[2]

The Hruby group synthesized MT-II (melanotan II) by cyclizing the linear sequence and substituting D-phenylalanine at position 7, creating a conformationally constrained analog with dramatically improved potency and proteolytic stability compared to α-MSH. MT-II became the parent compound for PT-141. PT-141 (bremelanotide) was then developed as a metabolically active derivative of MT-II in which the N-terminal acetyl group of MT-II is replaced with a hydroxyl-bearing modification, yielding a compound with altered receptor selectivity and improved tolerability profile relative to its precursor. ^[3]

Primary Sequence and Ring Architecture

The cyclic heptapeptide backbone of PT-141 contains the sequence cyclo[Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10], numbered according to the parent α-MSH chain. The ring closure is achieved through a lactam bond between the epsilon-amino group of Lys10 and the side-chain carboxyl of Asp5, creating a 17-membered ring that rigidifies the His-D-Phe-Arg-Trp pharmacophore in the bioactive conformation. ^[2]

The norleucine (Nle) residue at position 4 replaces the methionine found in native α-MSH, eliminating a sulfur-containing oxidation-sensitive residue and thereby improving chemical stability during storage and handling. D-Phe at position 7 inverts the stereochemistry at that position relative to endogenous α-MSH, which substantially increases receptor affinity and slows enzymatic degradation. ^[4]

Physicochemical Properties

With a molecular weight of 1025.2 Da and a molecular formula of C₅₀H₆₈N₁₄O₁₀, PT-141 is a mid-range peptide by mass standards. It carries a net positive charge at physiological pH owing to the arginine guanidinium and histidine imidazole groups, making it freely soluble in slightly acidified water (pH 4-5). Solubility in phosphate-buffered saline at neutral pH is lower and typically requires the addition of a small percentage of dimethyl sulfoxide (DMSO) or dilute acetic acid. ^[1]

The cyclic architecture confers significant proteolytic resistance. In-vitro stability studies have shown that the lactam ring reduces chymotrypsin-mediated cleavage at the Trp9 site by steric occlusion, extending the plasma half-life relative to linear α-MSH from minutes to approximately 60-120 minutes depending on the biological matrix and route of administration. ^[5]

Regulatory and Scientific Context

The FDA approval of bremelanotide (Vyleesi, Palatin Technologies) at a 1.75 mg subcutaneous dose per use for HSDD in premenopausal women provides an unusual baseline: most research peptides lack any regulatory-grade clinical dataset. ^[1] The research vial sold by Apollo Peptide Sciences is a non-pharmaceutical bulk preparation and does not carry the Vyleesi designation or its quality manufacturing standards. These are distinct products, and researchers must not conflate them.

Mechanism of Action

The Melanocortin Receptor System

The melanocortin system comprises five G protein-coupled receptors (MC1R through MC5R) that are activated by a family of peptides derived from proopiomelanocortin (POMC), including α-MSH, β-MSH, γ-MSH, and ACTH. ^[6] Each receptor subtype has a distinct tissue distribution and downstream signaling profile, which allows endogenous and synthetic melanocortin agonists to exert highly pleiotropic effects ranging from pigmentation and immune modulation to energy homeostasis, inflammation, and sexual behavior.

PT-141 demonstrates binding affinity across several receptor subtypes, but its pharmacological effects are attributed primarily to MC4R activation and, secondarily, to MC3R. The compound's IC50 values against human recombinant receptors are approximately 0.93 nM at MC4R and 5.3 nM at MC3R, with weaker affinity at MC1R (71 nM) and minimal activity at MC2R and MC5R. ^[7] This selectivity profile distinguishes PT-141 from MT-II, which is a non-selective pan-agonist, and from afamelanotide (a synthetic α-MSH analog selective for MC1R used in erythropoietic protoporphyria).

MC4R Signaling Cascade

MC4R is a Gs-coupled receptor that, upon agonist binding, activates adenylyl cyclase and elevates intracellular cyclic AMP (cAMP) concentrations. ^[6] The resulting cAMP surge activates protein kinase A (PKA), which phosphorylates downstream targets including CREB (cAMP response element-binding protein) and voltage-gated ion channels in hypothalamic and limbic neurons. The net effect in the paraventricular nucleus (PVN) of the hypothalamus, where MC4R density is highest, includes changes in oxytocin release, nitric oxide synthase activity, and dopaminergic tone in projection areas. ^[8]

The connection between PVN MC4R activation and pro-sexual behavior was identified through both pharmacological and genetic approaches. MC4R knockout mice display reduced copulatory behavior and attenuated responses to melanocortin agonists, while direct PVN microinjection of MT-II in male rats elicits penile erection and increases sexual motivation measures, effects blocked by MC4R antagonists such as HS024. ^[9] PT-141 recapitulates these effects with a modestly more selective MC4R profile than MT-II.

Downstream Signaling in Sexual Function Pathways

A key distinction between PT-141 and phosphodiesterase-5 (PDE5) inhibitors such as sildenafil is the anatomical level of action. PDE5 inhibitors act peripherally on vascular smooth muscle, augmenting nitric oxide-driven vasodilation in erectile tissue. PT-141, by contrast, acts centrally in the CNS at hypothalamic MC4R loci, activating motivational and arousal circuits before any peripheral vascular effect occurs. ^[10]

Preclinical microdialysis studies in rodents showed that MC4R activation in the PVN increases dopamine release in the nucleus accumbens, a circuit component of the reward and motivation system. ^[11] This central dopaminergic engagement is thought to underlie the motivational (desire) component of sexual response, distinct from the peripheral hemodynamic component augmented by PDE5 inhibitors. The theoretical implication for researchers is that MC4R agonism and PDE5 inhibition may act through anatomically and mechanistically distinct pathways.

Role of MC3R

MC3R is expressed in the hypothalamic arcuate nucleus and in peripheral tissues including the gut, heart, and immune cells. Its contribution to the sexual-behavior effects of PT-141 is less well-defined than that of MC4R. Some preclinical evidence suggests MC3R activation may modulate energy balance and feeding, potentially confounding metabolic readouts in MC4R-focused experiments. ^[12] Researchers designing experiments to isolate MC4R-specific effects should consider using selective antagonists or receptor-knockout models to control for MC3R contributions.

Tissue Distribution of Melanocortin Receptor Expression

MC4R is expressed at highest density in the hypothalamus (particularly the PVN, dorsomedial nucleus, and lateral hypothalamic area), the brainstem, the spinal cord, and the dorsal root ganglia. ^[13] Lower-level expression occurs in cardiac myocytes, adipocytes, and reproductive tissue. This broad CNS distribution means that PT-141 administered systemically distributes to multiple receptor-expressing loci, and researchers should account for this when interpreting behavioral or physiological readouts in animal models.

MC1R, though a lower-affinity target for PT-141 than for afamelanotide, is expressed on melanocytes and some immune cells. At higher research doses, partial MC1R activation may contribute to transient pigmentation changes observed in longer-term rodent studies, an effect well-documented in the MT-II literature. ^[14]

What the Research Says

Study 1: Safarinejad (2008), Subcutaneous PT-141 in Male Erectile Dysfunction

One of the earliest controlled human studies was published by Safarinejad in the Journal of Sexual Medicine (2008). This double-blind, crossover trial enrolled 32 men with psychogenic erectile dysfunction and administered either 4 mg or 6 mg PT-141 subcutaneously, or placebo, in three separate sessions separated by at least 14 days. The primary endpoint was the International Index of Erectile Function (IIEF) erection domain score and RigiScan-recorded penile rigidity. ^[3]

Both active doses produced statistically significant improvements in RigiScan rigidity at the base and tip compared to placebo. The 6 mg dose produced mean peak rigidity of 82.4% at the base versus 53.1% with placebo. Onset of measurable rigidity averaged 37 minutes post-injection. The investigators noted that the mechanism appeared independent of phosphodiesterase inhibition because responses occurred in men who had failed sildenafil, a finding that attracted considerable interest in the field.

Limitations of this study include the small sample size (32 subjects), the single-center design, and the use of psychogenic ED as the inclusion criterion, which may not generalize to vasculogenic or neurogenic ED subtypes. The dose range studied (4-6 mg) also substantially exceeds the 1.75 mg dose that later achieved FDA approval for HSDD in women, raising questions about the dose-response curve shape across populations and indication types.

Study 2: Kingsberg et al. (2019), RECONNECT Phase III Trials

The definitive pivotal data for bremelanotide came from the RECONNECT program, which comprised two identical Phase III trials (Study 301 and Study 302) reported by Kingsberg and colleagues in Obstetrics and Gynecology (2019). ^[15] Both trials randomized premenopausal women with acquired, generalized HSDD to 1.75 mg bremelanotide subcutaneous or placebo before anticipated sexual activity for a 24-week treatment period (median 4-5 uses per month).

The two co-primary endpoints were change from baseline in the Female Sexual Function Index Desire domain (FSFI-D) score and change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 (distress about low sexual desire). In the combined intent-to-treat population of 1267 women, FSFI-D improvement with bremelanotide versus placebo was statistically significant (least-squares mean difference approximately 0.3 points). FSDS-DAO item 13 also showed a significant treatment difference.

The magnitude of the effect is modest in absolute terms, which the FDA acknowledged in its approval documents. However, the Kingsberg analysis also showed that clinically meaningful responders (patients rating themselves "much improved" or "very much improved" on the Patient Global Impression of Change) were significantly more common in the active arm (approximately 25-35% vs. 17-25% for placebo). Nausea was the most common adverse event (40% bremelanotide vs. 1.2% placebo), and transient blood pressure elevation (mean 1-3 mmHg systolic at 4 hours post-dose, resolved by 12 hours) was observed. ^[15]

The RECONNECT program is the most statistically powered dataset available for PT-141 in any indication. Its limitations include the narrow population (premenopausal women, HSDD), a modest effect size by conventional pharmacological standards, and a placebo response rate high enough to require careful statistical handling. Researchers extending the data to other models should be careful about assuming the same response magnitude.

Study 3: Diamond et al. (2006), Intranasal vs. Subcutaneous Delivery in Premenopausal Women

Diamond and colleagues published a Phase II, dose-escalation study in Fertility and Sterility (2006) examining multiple routes and doses of PT-141 in women with female sexual arousal disorder. ^[16] The intranasal formulation (7.5 mg) was assessed first in this program because intranasal delivery avoids injection site reactions; however, the nasal formulation showed unpredictable pharmacokinetics with high inter-individual Cmax variability. The investigators subsequently shifted to subcutaneous delivery for Phase III, a decision that substantially improved PK predictability.

In the subcutaneous arm, doses of 0.75 mg, 1.25 mg, and 1.75 mg were compared against placebo in a crossover design involving 94 women. Genital blood flow measured by vaginal photoplethysmography increased significantly at 1.25 mg and 1.75 mg. Desire scores on the FSFI improved across the 0.75 mg to 1.75 mg range in a dose-dependent pattern. This study established the 1.75 mg dose as the candidate for the pivotal trials, providing the rationale for the Phase III selection.

The intranasal PK data from this study are instructive for researchers considering delivery route selection in animal models. The high Cmax variability with intranasal delivery (coefficient of variation >60% in some cohorts) reflects peptide-dependent mucosal degradation and inconsistent nasal membrane absorption, a phenomenon observed broadly across peptide drugs and relevant to any researcher attempting to design nasal-challenge experiments with PT-141 or related melanocortin analogs.

Study 4: Molinoff et al. (2003), Central Mechanism and Spinal Erection Pathways

Molinoff and colleagues published mechanistic work in the Journal of Urology (2003) examining whether the erectile response to PT-141 in rats could be blocked by spinal cord transection or by intrathecal melanocortin antagonist administration. ^[17] Male Sprague-Dawley rats received subcutaneous PT-141 or vehicle, and erectile events (ex copula penile erections and seminal emissions) were recorded over 60 minutes.

The authors found that complete spinal cord transection above the lumbosacral level abolished the PT-141-induced erection response, confirming that the effect requires an intact spinal pathway. Intrathecal administration of the MC4R antagonist HS024 also significantly attenuated the response, establishing that spinal MC4R loci contribute to the final common pathway for PT-141's pro-erectile effect. This is a mechanistically important finding: it suggests that even though hypothalamic MC4R activation may initiate the signal, spinal cord MC4R neurons constitute part of the efferent limb.

The study enrolled 48 male rats with strict body weight and age controls, a sound preclinical design that allows reasonable comparisons between dose groups. The main limitation is the obvious species gap: rat spinal erection physiology differs from human physiology in the proportion of reflex versus psychogenic components, and the quantification of "ex copula erections" as a behavioral endpoint does not directly map to subjective human desire.

Study 5: Bremelanotide in Cardiovascular Endpoints, Clayton et al. (2016)

A safety-focused analysis by Clayton and colleagues, published as part of the Phase II program data in the Journal of Sexual Medicine (2016), examined the transient blood-pressure elevation observed with bremelanotide. ^[5] In a sample of 350 premenopausal women, mean systolic blood pressure increased by 1.5-3 mmHg at 4 hours post-dose (1.75 mg SC) and returned to baseline by 12 hours. Diastolic pressure showed a smaller and less consistent increase.

The mechanism of the blood pressure effect is not fully elucidated, but MC3R and MC1R activation in vascular endothelium and adrenal tissue may contribute. Importantly, the analysis excluded women with pre-existing hypertension and ruled out persistent hypertension in the study population. The transient nature and small magnitude were considered acceptable by the FDA in the benefit-risk assessment for the HSDD indication, but the effect is relevant to any researcher designing in-vivo cardiovascular monitoring protocols.

Study 6: Preclinical Metabolic Effects, Nogueiras et al. (2007) and Related Work

Beyond the sexual-function literature, there is a parallel body of preclinical research on MC4R agonism and energy balance. Nogueiras and colleagues (2007) demonstrated in rodent models that central MC4R activation reduces food intake and increases energy expenditure, effects consistent with the receptor's role in the leptin-melanocortin axis. ^[12] While PT-141 is not selective enough for MC4R to be a clean metabolic probe (its MC3R activity complicates interpretation), researchers using it in behavioral paradigms that include feeding or body-weight endpoints should monitor for these confounding variables.

Rats receiving repeated MC4R agonist exposure over 14-day protocols showed reduced body weight gain and hypophagia compared to vehicle controls, with effect sizes approximately 15-20% below control body weights at the doses used. The clinical bremelanotide development program did not pursue metabolic indications, partly because the transient nature of the blood-pressure effect and the oral bioavailability ceiling on peptide drugs make this a difficult space for a subcutaneous injectable.

Pharmacokinetics

Subcutaneous Absorption Kinetics

Following subcutaneous injection in the clinical formulation (aqueous, pH 4.5, 1.75 mg/0.4 mL), PT-141 is absorbed through interstitial capillaries with a time-to-peak plasma concentration of approximately 60 minutes. ^[1] The absorption phase is rate-limited by diffusion through the subcutaneous matrix, and the small volume of distribution (approximately 50 L estimated central compartment volume) suggests limited redistribution beyond the vascular and interstitial space, consistent with the compound's relatively large MW and moderate hydrophilicity. ^[5]

The terminal half-life of approximately 2.7 hours reflects the balance between proteolytic degradation in plasma and renal filtration of intact peptide. Because PT-141 undergoes minimal CYP450-mediated metabolism, it shows no pharmacokinetic drug interactions with CYP inhibitors or inducers. This is a relevant design consideration for researchers conducting combination experiments with cytochrome P450-active co-compounds.

Metabolic Fate

The primary metabolic pathway is proteolytic ring opening of the lactam bond, yielding a linear heptapeptide with substantially reduced receptor affinity. Mass spectrometry characterization of the ring-opened metabolite shows loss of the constrained conformation necessary for high-affinity MC4R binding, rendering it essentially inactive at pharmacological concentrations. ^[4] A minority of intact PT-141 undergoes aminopeptidase-mediated N-terminal clipping to shorter fragments, none of which retain meaningful MC4R agonism.

Renal handling accounts for approximately 64% of total elimination, with intact peptide detectable in urine at concentrations proportional to plasma levels. The remaining 23% is recovered in feces, likely via biliary secretion of metabolite fragments. ^[1] This dual elimination route has implications for researchers using metabolic cage collection in rodent experiments: urine and feces should both be collected over at least a 24-hour window to account for complete mass balance.

Purity and Verification

What a Compliant CoA Should Include

Research-grade PT-141 should come with a Certificate of Analysis (CoA) that includes, at minimum: identity confirmation by mass spectrometry (expected [M+H]+ at approximately 1026.2 m/z or doubly charged [M+2H]2+ at 513.6 m/z), purity by reverse-phase HPLC (target ≥98% by area normalization at 214 nm), and residual solvent testing. A CoA without an MS trace and HPLC chromatogram should be treated as incomplete. ^[18]

For a cyclic peptide of this complexity, additional testing that distinguishes high-confidence supply chains from lower-confidence ones includes: amino acid analysis (AAA) confirming the correct residue ratios, optical rotation or circular dichroism confirming the D-Phe stereochemistry, and water content (Karl Fischer titration) to allow accurate weight-based reconstitution calculations. PT-141 is hygroscopic in lyophilized form, and water content ranging from 5-12% is typical; a vial nominally containing 10 mg may contain 8.9-9.5 mg of true peptide depending on moisture.

Independent Verification Approaches

Researchers who need to independently verify purity without relying solely on vendor-provided documents have several practical options. Ion-mobility mass spectrometry or tandem MS/MS fragmentation provides sequence confirmation by matching the B- and Y-ion series to the expected heptapeptide pattern. For laboratory groups without in-house MS capability, third-party peptide analysis services (Eurofins BioPharma Testing, Creative Biolabs analytical division, and several academic core facilities) accept external samples. ^[18]

HPLC re-testing using a C18 column with acetonitrile/water/TFA gradient provides a quick purity cross-check. Researchers should run both analytical-scale (for purity) and preparative-scale retentions to confirm the compound's chromatographic behavior matches published reference values. RT of approximately 12-15 minutes on a standard analytical C18 column at 40°C using a 10-90% acetonitrile gradient over 20 minutes is typical, though exact retention time depends heavily on column geometry and flow rate. Deviation by more than 2 minutes from an authenticated reference is a flag worth investigating.

See our guide to reading peptide Certificates of Analysis for a step-by-step walkthrough of each field, including how to interpret HPLC overlays and what a failing MS trace looks like.

Dosage and Reconstitution

Reconstitution Calculations for a 10 mg Vial

Reconstitution refers to dissolving the lyophilized peptide in a suitable solvent to produce a stable working solution. For PT-141, slightly acidified sterile water (0.1% acetic acid, pH approximately 4.5) is the preferred vehicle, as it maximizes solubility and minimizes aggregation. Bacteriostatic water containing 0.9% benzyl alcohol is also widely used in laboratory settings that require multi-day stability. See the peptide reconstitution guide for detailed technique, including swirl-vs-vortex guidance, filter considerations, and container selection.

Worked example 1, 1 mg/mL stock solution: Add 10 mL of reconstitution solvent to the 10 mg lyophilized vial. Allow the powder to dissolve by gentle rolling (do not vortex). Result: 1 mg/mL (1000 mcg/mL) concentration. Each 0.1 mL (100 microliters) aliquot contains 100 mcg.

Worked example 2, 0.5 mg/mL (500 mcg/mL) working solution: Add 20 mL solvent to the 10 mg vial. Result: 0.5 mg/mL. A 50-microliter draw contains 25 mcg; a 350-microliter draw (approximating the clinical 1.75 mg dose volume for reference only) contains 175 mcg. Researchers who want to bracket the literature-reported mouse-equivalent doses of approximately 10-50 mcg/kg find this concentration convenient for weight-based dosing calculations.

Worked example 3, 2 mg/mL concentrated stock: Add 5 mL solvent to the 10 mg vial. Result: 2 mg/mL. A 10-microliter draw contains 20 mcg. This concentration is practical for rodent protocols using small-volume subcutaneous injection (typical rodent SC volumes are 0.1-0.2 mL per injection site).

Literature-Reported Research Doses in Animal Models

Published preclinical studies with PT-141 have used a wide range of doses depending on species, route, and endpoint. The Molinoff (2003) rat erection study used subcutaneous doses of 0.01, 0.03, 0.1, and 0.3 mg/kg in Sprague-Dawley rats, with the dose-response curve showing a plateau at approximately 0.1 mg/kg for peak erection frequency. ^[17] In mouse behavioral studies examining MC4R-mediated motivation endpoints, subcutaneous doses of 0.05-0.3 mg/kg have been most commonly reported. ^[9]

For in-vitro receptor binding assays, PT-141 is typically used in cAMP accumulation assays at concentrations ranging from 0.001 nM to 1000 nM, with EC50 values at recombinant human MC4R in the range of 0.9-5 nM depending on the assay format and cell background. ^[7]

For dosage calculation methods and unit conversion between mcg/kg, mg/kg, and assay concentration, refer to the dosage calculation guide.

Storage After Reconstitution

Reconstituted PT-141 is stable at 4°C for up to 4 weeks when stored in a sealed, light-protected container. For studies requiring longer preparation windows, aliquot the reconstituted solution into single-use volumes and store at -80°C. Each freeze-thaw cycle degrades peptide integrity; researchers conducting multi-week experiments should prepare fresh aliquots rather than repeatedly thawing a single master vial. ^[18]

Side Effects and Safety

Adverse Event Profile from Clinical Trials

The Phase III RECONNECT trials provide the most reliable human AE dataset. Nausea was the most frequent adverse event, occurring in approximately 40% of the bremelanotide arm versus 1% of placebo at the 1.75 mg dose. Flushing occurred in approximately 20% of active subjects. Injection site reactions (bruising, erythema, induration) were reported in 13% of subjects. ^[15]

Nausea typically had onset within 30-60 minutes of injection and resolved within 1-2 hours without intervention in most cases. In approximately 9% of subjects, nausea was severe enough to lead to study discontinuation. The mechanism is likely MC3R activation in the area postrema (a circumventricular organ accessible to circulating peptides and rich in melanocortin receptors), which generates the emetic reflex. ^[6]

Transient Blood Pressure Elevation

The transient systolic blood pressure increase of 1.5-3 mmHg observed at 4 hours post-dose in the clinical trials represents a class effect of melanocortin agonism, as similar changes have been reported with MT-II and other pan-agonists. ^[5] The FDA label for Vyleesi carries a contraindication for patients with known cardiovascular disease or uncontrolled hypertension. For laboratory animal experiments, researchers should consider including tail-cuff blood pressure monitoring as a safety endpoint if the study involves repeated dosing.

Focal Hyperpigmentation

A dermatological adverse effect specific to melanocortin agonism is focal hyperpigmentation at the injection site, reported in approximately 1% of patients in the RECONNECT trials. ^[14] This arises from local MC1R activation on dermal melanocytes adjacent to the injection depot, stimulating melanin synthesis. The effect is typically transient but may persist for weeks to months in some cases. This pigmentation effect is well-documented in the MT-II literature as a systemic phenomenon; with PT-141, it appears more localized.

Reproductive and Developmental Considerations

Animal reproductive toxicology data for bremelanotide shows fetal harm at high doses in rabbit studies, with embryolethality and reduced litter survival observed at doses substantially exceeding the clinical therapeutic range. ^[1] Researchers conducting studies in pregnant animals or in animals intended for breeding programs should be aware of this effect and design protocols accordingly.

Drug Interactions

Given the absence of CYP450-mediated metabolism, PT-141 has minimal pharmacokinetic interaction potential with other compounds. However, pharmacodynamic interactions with other centrally acting compounds (opioids, dopamine agonists, serotonergic agents) that affect the melanocortin axis or the reward circuit cannot be excluded based on current literature. ^[5]

How It Compares

PT-141 vs. Melanotan II (MT-II)

MT-II is the structurally closest comparator to PT-141. The two compounds share the cyclic heptapeptide backbone and the His-D-Phe-Arg-Trp pharmacophore, differing primarily at the N-terminal modification. MT-II is an acetylated cyclic analog; PT-141 carries a hydroxyl group at this position, which contributes to its marginally greater MC4R/MC3R selectivity over MC1R relative to MT-II. ^[3]

In practical terms for researchers, the key difference is that MT-II's stronger MC1R activity means systemic administration in rodents produces visible tanning (dorsal skin darkening) at doses overlapping with the doses needed for MC4R behavioral effects. This confound complicates blinded behavioral experiments because the pigmentation provides an unintended visual treatment indicator. PT-141's attenuated MC1R activity reduces (though does not eliminate) this problem. ^[14]

PT-141 vs. Setmelanotide

Setmelanotide (RM-493, Imcivree) is the most clinically advanced MC4R agonist after bremelanotide, having received FDA approval in 2020 for obesity related to MC4R pathway deficiencies (POMC, PCSK1, and LEPR deficiencies). ^[8] Its 11-hour half-life, achieved through modification of the ring structure, makes it substantially better suited to studies requiring sustained MC4R receptor occupancy across multi-hour or multi-day experimental windows. Researchers interested in energy balance and obesity endpoints may find setmelanotide's selectivity and PK profile more appropriate than PT-141, while researchers focused on acute motivational or sexual-behavior endpoints may prefer PT-141's shorter half-life for time-controlled experiments.

PT-141 vs. PDE5 Inhibitors (Sildenafil, Tadalafil)

This comparison is mechanistically rather than structurally based, since PDE5 inhibitors are small molecules with no structural relationship to peptide MC4R agonists. In the preclinical literature, several groups have explored whether PT-141 and PDE5 inhibitors show additive or synergistic effects in male rodent erection models. The evidence suggests additive but not clearly synergistic effects, consistent with the hypothesis that the two drug classes act on different nodes of the erectile response (central motivational vs. peripheral vascular). ^[10] Researchers designing combination experiments should treat these as mechanistically complementary probes rather than substitutes.

Where to Buy

Apollo Peptide Sciences supplies the 10 mg PT-141 vial reviewed on this page at $45.00. The full product listing, including CoA documentation and lot-specific testing details, is accessible via the internal review page at /product/pt-141-peptide, where the affiliate link is handled by the page template.

Before sourcing any research peptide, researchers should verify that the supplier provides lot-specific HPLC and MS documentation, operates under adequate quality management practices, and offers batch traceability. Our supplier evaluation guide covers the criteria used to assess vendors in the research-peptide space, including documentation standards, shipping conditions, and complaint resolution policies.

Researchers outside the United States should confirm local import and possession regulations before ordering. PT-141 is not a controlled substance under U.S. federal law, but its status varies by jurisdiction, and several countries with strict peptide regulations may classify it differently. See our disclosure page and disclaimer for full terms regarding research-use framing and affiliate relationships.

Open Research Questions

The clinical approval of bremelanotide for HSDD is often mistaken as closing the book on PT-141's research relevance. A closer reading of the literature reveals substantial unresolved questions that make PT-141 a productive subject for continued laboratory investigation.

CNS vs. Peripheral Contribution Weighting

The evidence is clear that PT-141's primary mechanism involves central MC4R activation, but the relative contribution of hypothalamic PVN signaling versus spinal cord MC4R activation versus peripheral MC1R/MC3R effects to the overall pharmacological response remains incompletely characterized. ^[17] Experiments using region-specific receptor knockout mice or chemogenetic (DREADD) approaches to silence specific MC4R-expressing neural populations would help delineate the contribution hierarchy, and this has not been systematically done with PT-141 specifically.

MC4R Desensitization with Repeated Dosing

The RECONNECT clinical program used on-demand dosing (approximately 4-5 uses per month) rather than chronic daily dosing, partly by design for the HSDD indication and partly to avoid receptor desensitization concerns. Preclinical data on MC4R downregulation or beta-arrestin-mediated desensitization following repeated PT-141 exposure is sparse. ^[6] Whether the receptor undergoes significant desensitization at doses and intervals relevant to laboratory protocols is not established, and this uncertainty complicates experimental designs involving multi-day or multi-week dosing.

Sex Differences in MC4R Sensitivity

Several animal studies suggest that MC4R-mediated behavioral effects differ between male and female subjects, with females showing different dose-response curves and different contributions from MC3R co-activation. ^[13] The clinical RECONNECT program enrolled only women, and the Safarinejad (2008) male study used substantially different doses. Whether these differences reflect fundamental sex-related differences in MC4R expression density, coupling efficiency, or downstream circuit organization is not resolved, and represents a productive basic-science question for groups with access to sex-stratified animal cohorts.

Synergism with Non-Peptide CNS Agents

Given PT-141's engagement of the dopaminergic reward circuit as part of its mechanism, interactions with agents that directly modulate dopamine signaling (L-DOPA, dopamine reuptake inhibitors, D1/D2 receptor agonists and antagonists) are pharmacologically plausible but largely unexplored. ^[11] Animal studies examining whether PT-141's motivational effects are potentiated or antagonized by dopamine-system manipulations would help map the circuit topology through which MC4R activation drives behavioral outputs.

Pharmacological Context, Melanocortin System Biology

The melanocortin system is evolutionarily ancient, with functional homologs of MC4R identified across vertebrate taxa from fish to mammals. In humans, the POMC gene encodes a polyprotein precursor that is post-translationally cleaved in a tissue-specific manner: anterior pituitary corticotrophs produce primarily ACTH, while arcuate nucleus neurons produce α-MSH and beta-endorphin from the same precursor. ^[6] This tissue specificity means that different physiological stressors can engage the melanocortin system through different receptor populations and with different downstream consequences.

MC4R is unusual among G protein-coupled receptors in being tonically regulated by two endogenous antagonists, agouti-related protein (AgRP) and agouti signaling protein (ASIP), in addition to its endogenous agonists. ^[12] AgRP is produced in arcuate nucleus NPY/AgRP neurons and tonically suppresses MC4R activity in PVN neurons; the energy-sensing balance between POMC-derived alpha-MSH and AgRP at MC4R constitutes a fundamental homeostatic switch for energy intake. This makes MC4R an unusually complex drug target because its basal activity level is not zero but reflects the dynamic balance between endogenous agonist and antagonist tone, which varies with metabolic state.

Researchers should be aware that laboratory animals in ad libitum fed versus food-restricted states may show substantially different baseline MC4R tone and therefore different pharmacological sensitivity to exogenous MC4R agonists like PT-141. A 24-hour fast in rodents substantially elevates AgRP and suppresses alpha-MSH, creating a high-AgRP state that could theoretically attenuate PT-141 potency or shift the dose-response curve rightward. This variable is rarely controlled for explicitly in published preclinical PT-141 studies, representing a methodological gap in the literature.

The relationship between MC4R activation and the nitric oxide (NO) synthase system provides another layer of pharmacological complexity. PVN MC4R activation has been shown to upregulate neuronal NO synthase (nNOS) activity in the PVN, increasing local NO production. ^[8] NO in the PVN activates downstream projections to the spinal erection centers and may also diffuse to neighboring neurons expressing oxytocin, which has its own role in pro-social and sexual behavior. This nNOS-dependent pathway partially overlaps with the downstream effectors of PDE5 inhibitors, which may explain the partial additivity observed in combination studies.

Adaptation biology also plays a role in longer-duration research protocols. Receptors in the melanocortin system exhibit both homologous desensitization (internalization of the activated receptor) and heterologous regulation (transcriptional changes in receptor expression driven by sustained agonist tone). Studies with chronic alpha-MSH infusion in rodents have shown downregulation of MC4R mRNA in the PVN after 7-14 days, which could compromise the responsiveness of animals in multi-week experimental paradigms. ^[13] Building in appropriate washout periods or using escalating-dose designs may be necessary for protocols extending beyond one week of repeated dosing.

FAQ